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A brief review of past and present immunosuppressive treatments, including corticosteroids, 
cyclosporine A, and tacrolimus as they relate to liver transplantation is presented. The most 
common and detrimental side effects are presented for each therapy, and a method to reduce 
these adverse effects is proposed. As a method of drug delivery targeted to the liver, 
rnethylprednisolone is joined to a 70,000 Da dextran molecule through a succinic acid linker 
to form Dextran-methylprednisolone succinate @exMPS). A newly developed reversed- 
phase HPLC assay is validated, and is capable of simultaneous measurement of 
rnethylprednisolone (MP), methylprednisolone succinate (MPS),  methylprednisone (MPN), 
and corticosterone (CST) in addition to an internal standard (IS), triamcinolone acetonide. 
Ratios between drug plasma concentration and IS peak area were determined to be linear in 
the range of 0.1-4 pglml for MP and M P S ,  and 0.1- 1.0 pg/ml for MPN and CST. Assay 
intra- and inter-run errors were less than 8%, demonstrating its accuracy and precision. The 
efficiency of the assay was determined by analysis of samples with and without the extraction 
steps. All components were at least 80% extracted. Application of the assay to in vitro 
hydrolysis experiments included DexMPS incubation in rat blood and phosphate buffer, and 
in rat liver lysosomes and various buffers. The half-life ofDexMPS in blood was determined 
to be approximately 25 hours, and breakdown is most likely caused by chemical hydrolysis. 
The hydrolysis of MPS to MP is thought to be enzymatic, based on 1 0-fold faster breakdown 
in blood than in buffer. No significant hydrolysis was observed in isolated lysosomes for 
DexMPS or MPS. In addition, preliminary studies regarding rat spleen lymphocyte isolation 
and mitogen stimulation were performed. Optimum conditions for culture of spleen 
lymphocytes require RPMI-1640 to be supplemented with 2.5% rat serum. Separation of rat 
liver cells was accomplished by perfbsion of the liver with HEPES buffer containing 
collagenase, followed by centrihgation through a density gradient of Percoll to yield 
populations of hepatocytes (93% pure, with 80% viability) and Kupffer cells (98% pure, with 
92% viability). Together, these experiments provide a framework for examining the delivery 
of DexMPS to the liver, and measuring the effect of the DexMPS hydrolysis in vivo. 
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INTBWODUCIIION AND BACKGROUND 
Organ transplants are a large part of modern medicine. The ability to replace one or 
more non-functional, diseased, or damaged organs with those from a donor demonstrates the 
triumph of man over death. A closer look at these life saving procedures reveals that the liver 
transplant is among the most complex and costly of all surgeries (1). In addition to the 
hospital charges for the initial surgery and associated treatments, a liver transplant recipient 
can expect bills to total $200,000 (2); much more if severe complications arise. Contrary to 
public opinion, there are many causes for liver transplants, including nonalcoholic cirrhosis, 
alcoholic cirrhosis, biliary atresia, tumors, among others (3). 
Problems associated with organ transplantation are common. In fact, it is estimated 
that up to 50% of  all transplants would result in rejection if untreated (4). The basis of this 
problem is simple: the recipient mounts an immune response against the graft and attempts 
to destroy the foreign tissue. This occurs when host lymphocytes, especially cytotoxic T cells, 
recognize various surface antigens on the graft tissue. These antigens, genetically encoded 
in the HLA complex, are referred to as the tissue type. Similar to blood typing, an ideal 
transplant would involve matched haplotypes. This rarely happens, as it requires a genetically 
identical donor and recipient. Even in the case of closely matched tissue types, rejection can 
occur when host T cells recognize minor histocompatibility markers. In short, the host's 
immunologic response against the graft involves a cell-mediated response with two major 
steps. First, those lymphocytes that are able to recognize the transplanted tissue as foreign 
or altered-self cells are stimulated to differentiate and reproduce. mer this period of 
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sensitization, the mature cytotoxic lymphocytes attempt to destroy the foreign cells through 
directed release of perforins and granzyrnes (S), causing what is known as rejection. Acute, 
or cellular, rejection usually occurs within 4 weeks of the transplant, and affects up to 70% 
of all liver transplants (6). It is often reversible, especially if treated in the early stages. In 
contrast, chronic or ductopenic rejection is most often irreversible, requiring 
retransplantation. Fortunately, chronic rejection occurs in less than 16% of liver transplants 
(1). Interestingly, those patients who develop chronic rejection to primary transplants often 
battle it again in secondary and tertiary grafts (7). 
After surgical techniques developed sufficiently to allow organ removal and 
replacement, and the mechanisms of the immune system became known, the need for the 
ability to suppress the immune response became apparent. During the 1970's the first widely 
accepted treatment consisted of corticosteroid therapy. Prednisone, often accompanied by 
azathioprine, was the most successfbl(7). However, this treatment was associated with a 
high incidence of rejection, poor graft survival, and poor patient survival. In addition, life 
threatening side effects were common. Early liver transplants demonstrated only a 30% one 
year survival rate (1). 
Corticosteroids, including prednisone, work by inducing lysis of lymphocytes, 
especially immature cells in the thymus (5). In humans, the primary effect of corticosteroids 
is to cause a significant decrease in the number of circulating lymphocytes; Corticosteroids 
are also potent anti-inflammatory agents due to their ability to reduce the killing capabilities 
of macrophages and neutrophils (5). In addition, T cell activation is decreased by suppression 
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of class I1 MHC molecules on macrophages. Azathioprine is a mitotic inhibitor which 
diminishes lymphocyte proliferation by blocking synthesis of inosinic acid. Both B and T cells 
are affected (5) .  
Side effects of steroid therapy include hyperglycernia, insulin resistance due to a 
lowered number of insulin receptors, decreased muscle uptake of glucose, and osteoporosis 
(1 ). Adrenal cortisol production is suppressed, causing ihbit ion of longitudinal growth in 
children. Recent evidence suggests the donated liver's catabolic abilities play a part in growth 
suppression; problems associated with breakdown of methylprednisolone lead to increased 
exposure to the steroid and more growth inhibition. This problem can be overcome through 
treatment with recombinant human growth hormone, but this treatment requires daily 
injections, is costly, and doesn't always work (4). 
A major breakthrough came in the early 1980's with the use of cyclosporine A. This 
drug works by blocking the interaction of calmodulin with calcium (8). The same study has 
shown it to inhibit L-2 gene transcription and RNA synthesis, preventing the activation of 
T cells. When combined with corticosteroids, dramatic increases in patient and graft survival 
were seen, with the 1 year patient survival rate up to  70% (2). In fact, the triple drug cocktail 
of cyclosporine, prednisone, and azathioprine is commonly used as the standard against which 
other immunosuppressive regimens are measured (7). In the later part ofthe decade, advances 
in anesthetic technology, intensive care management, and prophylaxis against infection, along 
with new guidelines for patient selection and better organ preservation allowed another 
increase in survival rates. Today's 1 year survival rate approaches 90% (2). Unfortunately, 
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treatment with cyclosporine A still leads to the development of a variety of adverse effects. 
The most common ones include renal toxicity, hypertension, and diabetes mellitus (8). 
The continuing search for an immunosuppressive agent without negative effects next 
led to tacrolimus. Although structurally different from cyclosporine, t acrolimus also affects 
calcium mobilization in the early steps of T cell activation (10). It is thought that these two 
drugs bind different proteins with a common enzymatic activity. Also known as FK506, 
tacrolimus has been shown to be as effective as cyclosporine A in preventing graft rejection 
when combined with a low dose of corticosteroids; only 1% of patients required 
retransplantation and 13% needed OKT3 (monoclonal antibody to the CD3 antigen of T cells) 
treatment versus 4% and 33% of cyclosporine treated patients (1 0). In addition, tacrolimus 
treatment is effective at concentrations 10 to 100 times lower than cyclosporine (9), and 
shows a lower incidence and severity of hypertension (7). When tacrolimus is used as the 
primary immunosuppressive agent, it shows slightly higher patient and graft survival when 
compared to cyclosporine in one study (1 0). However, increased nephrotoxicity and 
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neurotoxicity suggest that this method of treatment is not ideal. Again, problems such as 
diabetes mellitus, gastrointestinal toxicity, insulin resistance, and graft rejection are common. 
One possible benefit to use of tacrolimus is the potential to remove steroids from the 
long-term treatment. A steroid weaning study by Tzakis, et al. shows only 10% of patients 
using tacrolimus required corticosteroids 9 months after their transplant. In contrast, all but 
one of the patients treated with cyclosporine continued to use prednisone for the entire study 
period, 18 months. 
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The combination of tacrolimus with low doses of steroids was initially regarded with 
great enthusiasm. Lower steroid doses meant less inhibition of endogenous steroid 
production, and fewer incidences of hypertension leading to better quality of life for survivors. 
However, the high renal toxicity and the increase in patients developing diabetes rnellitus has 
caused this drug to be used more often as a rescue treatment for acute rejection. 
Other newly developed drugs are able to be used in this fashion also. Some of these 
include OKT3 combined with antilymphocyte globulin (1 I), mycophenolic acid (7), and 
rapamycin(9). These drugs are the last steps in treating rejection before retransplantation, and 
are considered only after intravenous bolus corticosteroid treatment has been shown to be 
ineffective. 
These methods of treatment have greatly increased both patient and graft survival. 
In addition, the occurrence and severity of side effects has been decreased to some extent. 
But, for the thousands of people affected by them, adverse effects are still all too prevalent. 
Therefore, continued research in the field of immunosuppression is needed. Goals for future 
methods must include not only improved graft and patient survival, but also an absence or 
decrease in side effects. 
One way to avoid many of these unwanted side effects would be to target the delivery 
of the immunosuppressive agent to the site of action. Research in this field has focused on 
colon-targeting in the past (1 2,13). Here, we propose a novel mechanism for liver-targeting. 
Dextran Use 
Dextrans are large glucose polymers which have been used for decades as blood 
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volume expanders (14). One important feature of dextrans is that they are able to be 
metabolized in vivo (1 5). Thus, an administered dose is gradually eliminated from the body. 
The mechanism of clearance is based on the size of the dextran (14-18). In the rat, dextrans 
with molecular weight of less than 20,000 D a  are removed from circulating blood by the 
kidneys. The glomerular filtration apparatus removes these dextrans quickly and efficiently. 
At 40,000 Da the dextrans are too large for this mechanism to be effective; renal pores are 
blocked (16). As found by R. Mehvar, the primary method of clearance for this type of 
dextran is fluid-phase endocytosis in the liver and spleen; the hepatic accumulation of 70 kDa 
dextrans is substantial (1 4- 1 8). Therefore, attaching an immunosuppressive drug to a dextran 
of that size could increase its delivery t o  the liver, and allow decreased doses with 
accompanying benefits such as reduced toxicity and other side effects. With this information, 
experiments were designed to test the following hypothesis: 
Dextran-methylprednisolone succinate (DexMPS) provides more sustained local 
immunosuppression than does rnethylprednisolone (MP).  
MATERIALS AND METHODS 
Methylprednisolone is currently available, and is commonly used conjugated with 
succinic acid (MPS) to make it soluble in viva This is helpful when synthesizing the 
DexMPS conjugate according to the method of McLeod (1 3). [See Figure 1, from (1 9).]  
Development of an HPLC assay 
The first step in this project was to  design a procedure for the analysis of several 
corticosteroids. Existing methods did not allow for simultaneous measurement of MPS and 
Methylprednlsolone Hemisuccinatc Dextran-Methylprednisoloue Conjugate 
Figure 1. Structures of l>exMPS, MPS, and MP. 
Methylprednisolone , Internal Standard 
(Triamcinolone Acetonide) 
Figure 2. Structures of CST, MPN, and IS. 
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MP in the same sample, were not able to measure MP and its metabolite methylprednisone 
(MPN) with MPS, or did not allow determination of corticosterone (CST) with the other 
steroids (20-22). Refer to Figure 2 for structures. However, these published assays provided 
a pool of ideas from which w e  designed a working procedure. We also tested a variety of 
other corticosteroids to find a suitable internal standard. For this assay, we chose 
triamcinolone acetonide as the internal standard (IS). The final procedure follows: 
In a 15 ml screw top test tube, 500 p1 plasma and 100 p1 IS (5 p g h l  in 10% acetic 
acid) were combined. Hexane (1 0 ml) was added, and samples were mixed on a rotary mixer 
for 10 minutes at 20 rpm. Next, the tubes were centrifuged for 3 minutes; the hexane (upper) 
layer was aspirated and discarded. Methylene chloride (8 rnl) was added to the plasma, then 
tubes were mixed on the rotary mixer for 20 minutes at 20 rpm. Samples were centrifuged 
for 10 minutes, then the plasma (upper) layer was aspirated and discarded. The rnethylene 
chloride was decanted into a clean tube containing 100 p1 glacial acetic acid, then evaporated 
to  dryness under nitrogen flow in a 37°C water bath. The residue was dissolved in 200 11 
mobile phase, then vortex mixed for 10 seconds. The liquid was transferred to a microhge 
tube, centrifbged for 3 minutes, then the supernatant was transferred to a clean HPLC vial. 
Samples were run on a 15 cm Hamilton PRP-1, 5 pm column with mobile phase of 
24: 76 acetonitri1e:O. 1 M sodium acetate, with flow rate of 1.5 mlimin. Steroids were detected 
at 250 nm using a Waters 484 W detector. Other equipment used included a 590 pump 
(Waters), and a Sil9A auto sampler (Shimadzu). Chromatographic data was managed using 
Millenium software. A sample chromatogram is shown in Figure 3. 
Mnutes 
. - 
Figure3 Example of Chromatogram for HPLC Assay. 
Assay validation studies 
This assay was tested for linearity of HPLC detector response compared to sample 
concentration. Accuracy, precision, and recovery were determined. Calibration curves of 
standard drug concentrations were prepared at concentrations ofO. 1,0.2,0.4,1,2,3,4 pg/rnl 
for M P S  and MP. MPN and CST were included at one-fourth the concentrations of lM1"S and 
MP, and were quantified at 0.1, 0.25,0.5, 0.75, and 1 pg/ml. All standards contained 100 
p1 IS at 5 pg/ml. Linear regressions for plots of detector response (area under the curve) vs 
predicted concentration were calculated for each drug. An example of a calibration curve is 
shown in Figure 4. Accuracy was determined from intrarun samples consisting of one 
calibration curve plus 5 each of standards O.1,0.4, 1 ,4  pg/ml M P S  that were run as samples. 
Precision was determined in a similar manner; 5 intermn sets consisting of one calibration 
curve plus one each of samples 0.1,0.4, 1,4 pg/ml. In a study of drug recovery, the ratio of 
peak height from processed M P S  standards to unprocessed standards was compared. 
Application of the HPLC assay 
The first condition examined was the hydrolysis of MPS to M P .  In vieo experiments 
were conducted with known concentrations of MPS that were incubated for 1 hour in a 3 7" C 
water bath. Samples of 1,2.5, 5, 7.5, and 10 pglml M P S  (MP equivalent) were incubated in 
either rat blood or isotonic phosphate buffer. One ml samples were taken at time 0, and after 
1 hour. Blood samples were centrifuged immediately at 4"C, yielding plasma which was 
mixed with IS and frozen until analysis. Buffer samples were simply mixed with IS and frozen 
until analysis by HPLC. Hydrolyzed MP was plotted vs MPS concentration. 
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The next experiment involved the measurement of hydrolysis products of DexMPS. 
This in vitro procedure called for incubation of known amounts of DexMPS in pooled rat 
blood or isotonic phosphate buffer for 3 hours. Concentrations of 2.5,5, 10,25, 50,75, and 
100 pg/ml (MP equivalent) were made. Sample preparation and analysis were as above. 
Measurements of D e w s  concentration (17) and released MP and MPS in blood were 
made. Corresponding values obtained from incubation in buffer were also determined. The 
rate of MP and MPS production was calculated by subtracting the amount of MP or M P S  
present in the time 0 sample from that present in the 3 hour sample, then dividing by 3 .  
Another use of the HPLC assay was measurement of MP and PIPS in frozen samples 
containing DexMPS. For this procedure, DexMPS was added to rat plasma at a 
concentration of 50 pg/ml MP equivalent. Triplicate samples were analyzed at time 0, and 
after 1, 3, 7, and 14 days of storage at -80°C. 
A final check on the analytical procedure was to compare standards in rat plasma to 
those in phosphate buffer with albumin. Pooled rat plasma was cleaned with charcoal as per 
Haughey and Jusko (21). The slope of calibration curves for each drug were compared 
between the two systems; their similarity confirms that albumin is an acceptable substitute for 
rat plasma. 
Isolation of lysosornes from rat liver 
In this experiment differential centrifbgation was used to extract lysosomes from a 
suspension ofwhole rat liver. Experiments similar to blood and buffer hydrolysis ofMPS and 
DexMPS were then performed using the purified lysosomes. It was hypothesized that 
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increasing the concentration of lysosomal enzymes by incubating the drugs in isolated 
lysosomes would result in an increase in the rate of hydrolysis. 
One of the keys to lysosome isolation is modification of their density. This is 
accomplished by the use of Triton m - 1 3 3 9  ( ~ ~ l ~ x a p o l ) .  The procedure is taken from that 
designed by Trouet (23) ,  with minor modifications. Once the liver fractions were isolated, 
their purity was checked with several enzyme assays. As reported by Trouet, the assays used 
include acid phosphatase activity for lysosornes, cytochrome oxidase activity for 
mitochondria, uricase activity for peroxisomes, and glucose-6-phosphatase for endoplasmic 
reticulum. 
Male Sprague-Dawley rats (200-225 g) were injected i.p. with Triton WR-1339, at 
a dose of 85 mg/kg body weight. Four days later, after being fasted overnight, the rats were 
euthanized with CO,. The livers were removed and weighed in cold 0.25 M sucrose, then cut 
into small pieces with scissors. Homogenization in 5 ml 0.25 M sucrose/g liver was 
completed using an electric hand-held homogenizer. This homogenate was centrihged at 
2645 rpm for 10 minutes (6500 g-min) at 4' C in a Sorvall Suprahge RC2. The supernatants 
were aspirated and saved, then the pellets were resuspended in 0.25 M sucrose (3 mVg liver). 
This mixture was centrifuged at 2300 rpm for 10 minutes (5000 g-min) at 4' C in the same 
centrikge. After combining the supernatant with tha t  from the previous centrifugation, it was 
diluted to a total of 10 ml/g liver, using 0.25 M sucrose. This liquid was the cytoplasmic 
extract, Fraction E. The pellets were suspended in approximately 50 m10.25 M sucrose and 
composed Fraction N, containing nuclei and cell debris. 
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Fraction E was then centrifuged at 27,000 rpm for 10 minutes (340,000 g-min), at 
4 O  C in a Beckman L5-65 ultracentrifuge with a Ti70 rotor. As the supernatant was 
aspirated, the pink fluffy layer covering the pellet floated off and was removed. The pellets 
were then washed by resuspension in 5 rn10.25 M sucroseJg liver followed by centrihgation 
at 27,000 rprn for 10 minutes. The supernatant and pink layer was combined with that from 
the previous step, and the volume measured. This was the PS fraction, which contained 
rnicrosomes and cell sap. 
The pellets were suspended in 1 ml45% sucroseJg liver. This mixture was placed into 
tubes for the Beckrnan SW28 rotor, and covered with 22 rnl 34.5% sucrose. Next, 14.3% 
sucrose was layered on top to within 2 mm of the top of the tube. The balanced tubes were 
then centrifbged at 24,000 rprn for 2 hours. During this time, the lysosomes floated to form 
a band between the 34.5% sucrose and the 14.3% sucrose layers. This band, Fraction T, was 
harvested using a Pasteur pipette. The remainder ofthe gradient and pellet was homogenized, 
yielding Fraction R which was made up of mitochondria and peroxisomes. For procedure 
overview, see Figure 5. 
Fraction Assays 
Protein Analysis 
The protein content of each fraction was determined using the Bradford method. One 
hundred p1 of diluted tissue fraction was added to 1 rnl dye concentrate plus 4 ml water. The 
absorbance at 595 nm was taken and converted to pg proteinlml using a standard curve based 
on bovine albumin. 
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Acid Phosphatase 
The acid phosphatase assay used was that reported by Trouet (23), with minor 
modifications. Rather than the 1 rnl used by Trouet, 0.5 ml tissue fraction was incubated with 
0.2 ml P-glycerophosphate, 0.1 ml2% wlv Triton X-100, and 1.1 ml water for 30 minutes 
in a 37°C water bath. At that time, the reaction was stopped with 10 rnl 8% TCA. In the 
case of blanks used to determine nonspecific phosphatase activity, the P-glycerophosphate 
was added after the TCA. The denatured proteins were sedimented by centrifucation (5000 
rpm, 10 minutes). One rnl of the supernatant was added to 1 rnl 2.5% w/v ammonium 
molybdate in 5N H2S04, 0.2 ml Fiske-Subbarow reducer (SIGMA chemical company), and 
7.8 ml water. After 10 minutes, the &, was read, allowing the pmoles of phosphate released 
to be determined as compared to a standard curve. 
Cytochrome oxzdzse 
The method employed by Trouet (23) was used for this assay. A standard solution 
of cytochrome c was reduced completely with sodium hydrosulfite. Three ml of this solution 
were placed in a 1 cm quartz cuvette with 20 p1 of tissue fraction. The absorbance at 550 nm 
was read every 30 seconds for 5 minutes. Next, a few grains of potassium ferricyanide were 
added to the cuvette to completely oxidize the remaining cytochrome c. The A,,, of the 
oxidized solution was subtracted from the earlier readings, then the pmoles of cytochrome 
c oxidized per minute was calculated for each fraction using a standard curve. 
Uricase 
Urate oxidase activity was measured in the same manner as by Trouet (23). In this 
assay, 25-100 p1 of tissue fraction was added to 0.2 rnl potassium phosphate buffer (0.5M) 
and water to make 3.0 ml. The A, of this mixture was read as a blank, then 10 pl of uric 
acid solution was added. The was read in 1 minute intervals for 10 minutes. These 
values were converted to pmoles of uric acid oxidized per minute for each fraction as 
determined by a standard curve. 
Glucose-6-phosphatase 
Phosphatase activity at non-acidic pH was determined as reported by Trouet (23). 
Using a calibrated glass centrifuge tube, 0.1 rnl of the substrate (glucose-6-phosphate) was 
mixed with 0.3 ml maleic acid buffer. This was brought to 37°C in a water bath, then 0.1 ml 
tissue fraction was added. This was incubated for 15 minutes in the water bath. The reaction 
was stopped with 1 ml8% TCA. Next the tubes were chilled in ice for 5 minutes, diluted to 
2.5 rnl, and centrihged at 5000 rpm for 10 minutes. One rnl of the supernatant was taken for 
phosphate analysis as described above. 
Isolation of lymphocytes from rat spleen and mitogen stimulation assay 
Lymphocyte Isolation 
The basic procedure followed was obtained from the SIGMA diagnostic procedure 
bulletin number 95 (24), which was designed for the isolation of human blood lymphocytes. 
Only minor modifications, such as use of a suspension of spleen tissue rather than a dilution 
of a whole blood sample and the use of RPMI-complete containing varying concentrations 
of rat serum rather than RPMI- 1640 for the final cell dilution, were needed to adapt it for use 
with rat spleenocytes. 
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This procedure uses a density gradient material, Histopaque (SIGMA chemical 
company), to separate lymphocytes from other cell types. In the case of human lymphocytes, 
a fresh blood sample (3rd)  was mixed with RPMI-1640 (5ml) then layered onto Histopaque 
(3rd).  During centrifugation, a layer of lymphocytes formed which was aspirated off, washed 
with RPMI- 1640, then recentrifbged. The resulting cell pellet was suspended in RPMI- 1640, 
diluted to the desired cell concentration and assayed for viability using trypan blue. 
Rat spleenocytes were isolated in a similar manner. The excised spleen was placed 
in HEPES buffered RPMI-1640 (25) and the tissue was disrupted using a stainless steel tissue 
grinder. The cells were collected in, and diluted with, 25 rnl RPMI-1640. Eight ml of the 
diluted spleenocyte suspension were layered onto 3 ml of Histopaque- 1077 in 15 rnl plastic 
conical centrifuge tubes. The tubes were centrihged at 400g (1500 rpm) at room 
temperature for 30 minutes using a swinging bucket type centrikge (Damon IEC HM-SII). 
The upper layer of  supernatant was aspirated and discarded, using a sterile pipette tip, to 
within 0.3 cm ofthe white band containing lymphocytes. This layer was transferred to a clean 
15 rnl centrifuge tube and mixed with 10 rnl of RPMI-1640. This mixture was centrifuged 
at 1500 rpm for 10 minutes at room temperature. Following removal of the supernatant by 
aspiration, the cell pellet was suspended in 1 ml of RPMI containing the appropriate 
concentration and type of serum, 2mM Glutarnine, and 1% penicillin/streptomycin (26), then 
diluted to a final cell concentration of 2x106 cells/ml. During the process of counting and 
diluting the cells, viability was checked using the trypan blue exclusion assay. 
Mitogen stimulation assay 
In addition to studies of human peripheral blood lymphocytes and rat spleen 
lymphocytes, experiments were done to determine the effects of using RPMI supplemented 
with 10% fetal calf serum, 2.5% rat serum, or 5% rat serum on the proliferation of rat 
lymphocytes. Rat serum was obtained from blood collected through cardiac puncture of ether 
anesthetized rats. Fetal calf serum was obtained from Diamond Labs (Des Moines, IA). 
One hundred pl of the cell suspensions were placed into the wells of a 96 well, flat 
bottom microtiter plate (Corning). An equal volume of mitogen was added in concentrations 
ranging kom 0 t o  20 pglrnl (27). Preliminary studies with human lymphocytes used 
phytohemagglutinin (PHA) and concanavalin A (Con A) (26). The rat lymphocyte studies 
used only Con A. The plates were then incubated in a 5% CO, atmosphere (Forma 
Instruments) at 3 7 O  C for 48 hours. Two pl of 'H-thymidine (1.000 mCi/ml, New England 
Nuclear Supplies) were added to each well, and the plate was incubated for an additional 18- 
20 hours (25). 
Following incubation, the lymphocytes were collected onto glass fiber filtermats using 
a S katron Cell Harvester. The filtermats were dried at room temperature for 40-45 minutes, 
then the sample disks were placed into plastic scintillation vials. Scintillation fluid (3 ml) was 
added to each vial, which was then capped for storage. 
Sample radioactivity was determined with 3 days of cell harvest using a Beckman LS 
1800 Liquid Scintillation Counter. The resulting counts per minute (cprn) were averaged for 
the replicate wells and plotted using Microsoft Excel as cpm v. mitogen concentration. 
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Liver cell isolation 
One method of analyzing the local effect of DexWS on the liver is t o  examine the 
availability ofDexMPS in liver endothelial cells and Kupffer cells. Concentrations of the drug 
can b e  measured through HPLC analysis, allowing conclusions to  be drawn regarding storage 
and breakdown of DexMP S, and its availability to lymphocytes. 
This procedure involved isolating and camulating a rat liver as described by Seglen 
(28) ,  with some modifications as proposed by Pertoft (29). The liver was perfbsed for 10 
minutes with calcium~collagenase free HEPES buffer, 50 ml/min in a single pass system. 
Perfusion with HEPES buffer with 0.7 g CaC1i2H20/L and 0.5 g collagenaseL in a 
recirculating manner followed. After 10 minutes, or when the liver began t o  fall apart, the 
perfhion was stopped. The liver cells were dispersed in a sterile plastic petri dish containing 
1 5 ml calcium free HEPES buffer with 1.5% BSA and 80 pg/ml DNAase. This suspension 
was passed through a double layer fine-weave nylon mesh which was then washed with 33 5 
ml HEPES buffer with albumin and DNAase. The diluted cells were centrifuged at 70g (660 
rpm) for 2 minutes at room temperature @eraus Sepatech 13.92 rotor). The supernatant, 
containing nonparenchymal (Kupffer) cells, was aspirated and pelleted at 400g (1 570 rpm). 
The original pellet of liver endothelial cells was washed twice in PBS. The washed LECs 
were suspended in PBS, then layered onto 16 ml70% Percoll (SIGMA chemical company). 
This preparation was centrihged at 800g (2300 rpm) for 10 minutes at room temperature, 
also in the HS 13.92 rotor. Contaminating NPCs and dead LECs remain on t o p  of the 
Percoll, allowing a pellet of hepatocytes to be harvested. See Figure 6 for clarification 
I:. 
Determination of cell purity and viability 
The determination of cell counts, purity, and viability was accomplished with a 
hemacytometer and trypan blue. Concentrated cell pellets were suspended in RPMI 1640, 
then 50 p1 of the cell suspension was mixed with 50 p1 trypan blue. Viable cells remained 
clear, dead cells were tinted blue. Cells were counted using the grids provided on the 
hemacytometer slide, then concentrations were calculated using the formula 
( Avg # of cells 1 4 grids ) x 2 x 10' = cells/ml 
where 2 is the dilution factor caused by trypan blue, and 10' is the factor of the 
hemacytometer slide which contains a volume of 0.1 rn13. 
RESULTS 
Development and validation of an EIPLC assay 
The HPLC assay developed is capable of simultaneous measurement of 4 
corticosteroids. All 5 assay components were baseline separated with little retention time 
variability observed. The limit of  quantitation is 0.1 pg/ml for all drugs. Accuracy and 
precision are within acceptable ranges (Tables 1 and 2), and recovery of the steroids during 
the extraction procedure exceeds 80% for all drugs (Table 3). 
Application of the HPLC assay 
The slope of the trend line for M P S  hydrolysis to MP (Figure 7) provides the rate 
constant of that reaction since it was allowed to proceed for one hour. However, a similar 
approach to D e w s  hydrolysis (Figure 8) does not provide the correct rates due to the 
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Table 1. Intrarun validation study data. 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
MP MPS MPN CST 
0.1 uglml 
0.0944 0.1070 0.1070 0.0960 
0.0050 0.0172 0.0106 0.0126 
5.3283 16.065 9.9567 13.156 
-5.60 7.00 7.00 -4.00 
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Table 2. Interrun validation study data. 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
Mean 
Standard Deviation 
Coefficient of Variation 
Percent Error 
MP MPS MPN CST 
0.1 luglrnl 
0.1032 0.1024 0.1036 0.1070 
0.0068 0.0095 0.0061 0.0099 
6.5863 9.2799 5.895 1 9.2282 
3.20 2.40 3.60 7.00 
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Table 3. Recovery of NPLC Standards. 
Average area units for 4 components 
MP MPS MPN CST 
Unprocessed 130366 131803 32205 36128 
Processed 
Ratio * 100% 
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capability of released M P S  to hydrolyze to MP. Using the known rate of lMPS hydrolysis, 
measured concentrations of DexMPS at time 0, and measured concentrations O M S  and MP 
after 3 hours of incubation, rate constants for DexMPS hydrolysis to MPS and MP can be 
estimated (Table 4). Also shown in Table 4 are estimated half-lives of MPS and DexhfPS in 
blood. These values were obtained using the equation: 
t , ,  = 0.693lrate. 
As expected, the half-life for DexMPS is substantially longer than that of M P S ,  due to the 
lack of dextranases in circulation, and the steric interference of the bulky dextran side chains 
with blood esterases. In the same manner, the release of M P S  and M_P from DexMPS occurs 
at nearly the same rate; they are cleaved by the same esterase acting at different ends of the 
succinic acid linker. 
The study of ex vzvo hydrolysis in frozen samples shows constant levels of M P S ,  hlP, 
and CST over the sampling period (Table 5). This indicates that collected samples can be 
acidified by addition of IS solution, then frozen for up to two weeks before analysis. 
Isolation of lymphocytes from rat spleen and mitogen stimulation 
All cell samples (rat and human) were determined to be greater than 95% viable after 
isolation, as judged by trypan blue exclusion. The first trial using human lymphocytes 
stimulated with Con A and PHA was successfUl in obtaining a dose-response curve, so hrther 
trials were not undertaken. Additional trials were conducted using rat spleen lymphocytes 
cultured in RPMI containing 10% FCS or varying amounts of rat serum. 
Table 4. Drug hydrolysis and half-lives in rat blood. 
Reactant/Product Rate Constant of Hvdrolvsis Half-life in hours 
MPS/1WP 0.118kr 5.9 
DexMPS/MPS O.O413/hr 48.5 
DexMPS/MP 0.0135/hr 51.3 
Table 5. HPLC analysis of DexMPS samples in rat blood. Average er vivo hydrolysis 
of three frozen samples (pg/ml). 
MPS MP CST 
0 Day 0.018 0.066 0.366 
1 Day 0.018 0.121 0.383 
3 Days 0.0 0.056 0.365 
14 Days 0.084 0.0 0.439 
Mean 0.034 0.056 0.391 
Standard Deviation 0.049 0.05 1 0.046 
Lives cell isolation 
Low speed centrifbgation is capable of pelleting the relatively large hepatocytes. 
Contamination of the supernatant containing Kupffer cells is low (see Table 6). Use of a 
single layer density gradient (70% Percoll) provides a quick, yet effective method of removing 
unwanted nonparenchymal cells and many dead hepatocytes from the parenchymal cell pellet. 
Isolation of lymphocytes from rat liver and mitogen stimulation assay 
The two assays for human lymphocyte proliferation using Con A showed dose 
response curves with peak mitogenic activity occurring when the concentration of Con A was 
10 pglml (see Figure 9). Trials using rat spleenocytes cultured in 10% FCS exhibited little 
proliferation (see Figure 10). The rat spleenocyte proliferation in rat serum exhibited peak 
growth when Con A at a concentration of2.5 pg/ ml was present in the wells (see Figure 1 1). 
DISCUSSION AND CONCLUSIONS 
HPLC assay 
This novel HPLC assay is usefbl for both in vitro and in vivo experiments. The 
extraction procedure is efficient enough to allow quantification of all four components in a 
range of concentrations. In addition, this procedure is unique in its ability to measure M P ,  
its precursor MPS, and one metabolite, MPN. Thus, it is of potential use for other 
researchers examining the in vivo breakdown of corticosteroids. 
Isolation of lysosomes from rat liver 
The method of isolation described by Trouet has been thoroughly tested since it was 
first proposed. Never the less, we double checked our fractions using the proposed enzyme 
Table 6. Liver cell isolation: Kupffer cells and hepatocytes. 
He~atocvtes Viability Kupffer cells Viability 
Original 
suspension 72% 86% 28% 96% 
Kupffer cell 
pellet 2% 100% 98% 92% 
Washed 
hepatocytes 93% 80% 
Average cpm-human lymphocytes 
0 
0 2.5 5 1 0  
mlcrogram/ml mltogen 
Con A 1 
2 0  - 
--O- Con A 2 
1 
, . - . - - . . . . . . . . . . - . . . - . . . . - .- - . . . - - -- . .. . . . - . . . .-  - . I.. 
J .  
. ... - . .-. . . . .. . , . 
Figure 9. Human blood lymphocyte stimulation, cells cultured in RPMI-1640 supplemenred 
with 10% fetal calf serum. 
t 
Avg cpm-rat lymphocytes in 10% FCS 
-7 
Figure 10. Rat spleen lymphocyte stimulation, cells cultured in RPMI- 1640 supplemented 
with 10% fetal calf serum. 
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tests after our first lysosome isolation. All samples were reasonably close to those predicted 
by Trouet (data not shown). In fact, our lysosomes had a 3 fold higher specific activity then 
expected. This was most likely a result of more efficient instruments in our lab as compared 
to those used 25 years ago by Trouet. Confident that our procedure worked, only the purity 
of lysosomes from future isolations was checked. 
Hydrolysis experiments similar to those in rat blood were set up to measure the release 
of MP from M P S  (10 pglml), and M P S  and MP from DexMPS (100 pg/ml) after incubation 
in isolated lysosomes. Preliminary studies showed no hydrolysis in 3 hours, so others were 
allowed to incubate for 12 and 24 hours. No significant difference in hydrolysis between 
drugflysosome solutions and drug/sucrose solutions samples was found, but hydrolysis was 
observed, Since the amount of drug released in 24 hours was not double that released in 12 
hours, enzyme efficiency in vitro was questioned, leading to continued studies at 12 hours. 
Efforts to increase hydrolysis of MPS and DexMPS in 1ysosomal contents included 
sonification of lysosomes to ensure release of their contents; use of fresh lysosomes rather 
than those frozen at -80°C; fresh lysosomes dialyzed against phosphate buffer to remove 
sucrose; fresh lysosomes that were filter centrihged to remove low MW contaminants 
(sucrose); and lysosornes obtained through a procedure not involving Triton WR- 13 3 9 
injection (30). Also included were experiments using acetate buffer, citrate buffer, acetate 
buffer plus Triton X- 100 (1 5), citrate buffer plus EDTA (3 l), and citrate plus Triton X- 1 00 
to dissolve the DexMPS and MPS. In all cases, we were unable to show any difference 
between incubation in lysosomes and buffer. 
Isolation of Lymphocytes from rat liver and mitogen stimulation assay 
The use of rat serum rather than fetal calf serum had 2 major effects. First, it shifted 
the peak of the dose-response curve from 10 pg/ ml to 2.5 pg/ ml Con A. Also, the rat cells 
were able to incorporate more radioactive thymidine in the presence of rat serum than fetal 
calf serum, indicating that more replication occurred. These two factors indicate that the 
proliferative ability of  the isolated lymphocytes is better determined by growth in rat serum 
supplemented RPMI than fetal calf serum supplemented RPMI. These experiments show that 
rat spleenocyte isolation using centrikgation and the density gradient material Histopaque is 
readily accomplished. Optimum conditions for mitogenic stimulation of the isolated cells 
consist of 2.5 vg/ rnl Con A, and RPMI supplemented with 2.5% rat serum. 
Liver cell isolation 
During the repeated centrihgation and washing steps the viability of the hepatocytes 
declines, partly due t o  the time needed to complete the steps. Fortunately, viability is not 
essential when measuring the cellular concentration of a large molecule like DexMPS. 
Final conclusions 
One experiment which can be set up using these procedures involves the 
administration of DexMPS or MP to  rats, followed by their sacrifice at various times from 0 
to 96 hours later. With the harvesting and culture of spleen lymphocytes, the effectiveness 
of the immunosuppressant can be measured. The MP effect should be overcome within 24 
hours (26), while the DexMPS effect is hypothesized to remain for several days. 
A second experiment could involve the harvesting of liver cells. The liver cell 
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isolation procedure can be applied to groups of rats sacrificed at 12 and 96-168 hours after 
DexMPS injection. These two time points would allow any change in the Kupffer cell: 
hepatocyte ratio to be seen. In addition to observing the ratio of cell populations, the isolated 
cell suspensions may be able to be substituted for plasma in the HPLC assay, allowing the 
presence of DexMPS, MPS, or MP to be determined. 
Together these procedures provide information concerning hydrolysis of a prodrug 
in experimental situations. They begin to examine the question of dextran conjugate stability 
and release of an active agent, and provide a base for future work regarding the long term 
effects and benefits of targeted drug delivery t o  the liver. Work yet to be completed 
concerning administration ofDexMPS to rats and the resulting local immunosuppression over 
time will reveal even more of this interesting puzzle. 
In addition, a novel HPLC assay was developed. It is extremely useful for analysis 
of DexMPS breakdown into MPS and MP, but can also be used for analysis of MPS 
breakdown to MP. It also has the potential to be modified for similar corticosteroid prodrug 
systems. 
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